向日葵(300111.SZ)拟收购兮璞材料100%股权及贝得药业40%股权 股票复牌

Core Viewpoint - The company Sunflower (300111.SZ) plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical through a combination of share issuance and cash payment, aiming to enhance asset quality and long-term development [1] Group 1: Acquisition Details - The acquisition involves purchasing 100% equity of Xipu Materials from six trading parties and 40% equity of Beid Pharmaceutical from Sunflower Investment [1] - Xipu Materials specializes in the research, manufacturing, and sales of high-end semiconductor materials, including high-purity electronic special gases and silicon-based precursors [1] - Beid Pharmaceutical, a subsidiary of Sunflower, focuses on the research, manufacturing, and sales of drugs for infections, cardiovascular issues, and digestive system disorders [1] Group 2: Strategic Implications - This transaction is expected to improve the asset quality of the listed company and promote its long-term development [1] - Post-transaction, the company will enter the high-end semiconductor materials sector, creating a second growth curve and accelerating the transition to new productive forces [1] - The move is anticipated to generate new profit growth points, thereby enhancing the company's sustainable profitability [1]